Published in Cancer Res on July 15, 2011
Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell (2015) 4.16
Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol (2013) 2.98
c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis. Blood (2014) 1.45
p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med (2013) 1.34
Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol (2014) 1.27
RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J Exp Med (2012) 1.20
Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ (2013) 1.11
New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology (2013) 1.10
Immunosurveillance and immunotherapy of tumors by innate immune cells. Curr Opin Immunol (2015) 1.10
PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst (2015) 1.02
The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells. Front Immunol (2014) 1.02
Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer. J Immunol (2013) 0.97
Molecular Bases for the Regulation of NKG2D Ligands in Cancer. Front Immunol (2014) 0.94
The effect of environmental chemicals on the tumor microenvironment. Carcinogenesis (2015) 0.91
Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron (2012) 0.87
Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers. Front Oncol (2012) 0.86
Immune surveillance of unhealthy cells by natural killer cells. Cold Spring Harb Symp Quant Biol (2013) 0.86
The modulation of the cell-cycle: a sentinel to alert the NK cells of dangers. Front Immunol (2013) 0.86
A forward genetic screen reveals novel independent regulators of ULBP1, an activating ligand for natural killer cells. Elife (2015) 0.83
Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia. Genes Immun (2014) 0.83
NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma. Biomed Res Int (2015) 0.81
Strategies to improve the immunosuppressive properties of human mesenchymal stem cells. Stem Cell Res Ther (2015) 0.80
Effect of ex vivo culture conditions on immunosuppression by human mesenchymal stem cells. Biomed Res Int (2013) 0.80
Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy. Cancer Biol Ther (2016) 0.78
Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat Rev Immunol (2016) 0.78
The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells. Oncoimmunology (2016) 0.78
Skin Cancer Risk Is Modified by KIR/HLA Interactions That Influence the Activation of Natural Killer Immune Cells. Cancer Res (2016) 0.77
Chemotherapy and Stem Cell Transplantation Increase p16(INK4a) Expression, a Biomarker of T-cell Aging. EBioMedicine (2016) 0.77
CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells. Oncogene (2016) 0.77
A novel facet of tumor suppression by p53: Induction of tumor immunogenicity. Oncoimmunology (2012) 0.77
HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. Eur J Immunol (2015) 0.76
A short half-life of ULBP1 at the cell surface due to internalization and proteosomal degradation. Immunol Cell Biol (2016) 0.76
Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment. Int J Mol Sci (2016) 0.76
Tumor suppressors control ULBP2, an innate surface ligand of the lymphocyte immune receptor NKG2D. Oncoimmunology (2012) 0.76
Expression and prognostic significance of unique ULBPs in pancreatic cancer. Onco Targets Ther (2016) 0.75
The Immune Interplay between Thyroid Papillary Carcinoma and Hepatic Fibrosis. PLoS One (2015) 0.75
p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells. Oncoimmunology (2016) 0.75
New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy. J Immunother Cancer (2015) 0.75
MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma. Oncoimmunology (2017) 0.75
Uncovering the immunotherapeutic cycle initiated by p19Arf and interferon-β gene transfer to cancer cells: An inducer of immunogenic cell death. Oncoimmunology (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med (2006) 6.54
Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol (2006) 5.00
Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A (2008) 2.99
Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol (2005) 2.55
The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. Blood (2003) 2.06
Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain (2011) 1.95
The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun (2012) 1.88
Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med (2012) 1.86
Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR. Nat Cell Biol (2008) 1.60
Retracted Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest (2004) 1.58
Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol (2012) 1.56
Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells. Blood (2008) 1.56
The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol (2009) 1.54
Dynamics of component exchange at PML nuclear bodies. J Cell Sci (2008) 1.47
Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy. PLoS One (2008) 1.47
Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol (2004) 1.43
Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res (2008) 1.40
Role of NK cell-activating receptors and their ligands in the lysis of mononuclear phagocytes infected with an intracellular bacterium. J Immunol (2005) 1.39
Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol (2011) 1.37
Vimentin expressed on Mycobacterium tuberculosis-infected human monocytes is involved in binding to the NKp46 receptor. J Immunol (2006) 1.34
The TREM-1/DAP12 pathway. Immunol Lett (2007) 1.33
NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells. J Immunol (2009) 1.27
Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences. J Proteome Res (2009) 1.27
FLASH links the CD95 signaling pathway to the cell nucleus and nuclear bodies. EMBO J (2007) 1.26
Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol (2009) 1.20
PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res (2003) 1.19
Coactivator function of RIP140 for NFkappaB/RelA-dependent cytokine gene expression. Blood (2008) 1.18
Role of nuclear bodies in apoptosis signalling. Biochim Biophys Acta (2008) 1.18
Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. J Exp Med (2005) 1.18
IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion. J Clin Invest (2014) 1.17
The NKp46 receptor contributes to NK cell lysis of mononuclear phagocytes infected with an intracellular bacterium. J Immunol (2002) 1.17
Homeodomain-interacting protein kinase 2 is the ionizing radiation-activated p53 serine 46 kinase and is regulated by ATM. Cancer Res (2007) 1.16
RORγt⁺ innate lymphoid cells acquire a proinflammatory program upon engagement of the activating receptor NKp44. Immunity (2013) 1.14
Characterization of the recognition of tumor cells by the natural cytotoxicity receptor, NKp44. Biochemistry (2007) 1.12
Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer (2008) 1.12
Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool. Glycobiology (2007) 1.12
Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect Dis (2009) 1.11
Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer (2009) 1.11
The human papillomavirus oncoprotein E7 attenuates NF-kappa B activation by targeting the Ikappa B kinase complex. J Biol Chem (2002) 1.11
Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. PLoS Pathog (2011) 1.11
IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res (2009) 1.09
Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer (2006) 1.08
Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One (2012) 1.08
H5-type influenza virus hemagglutinin is functionally recognized by the natural killer-activating receptor NKp44. J Virol (2007) 1.08
Natural killer cells and solid tumors. J Innate Immun (2011) 1.07
Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood (2013) 1.06
Non-T cell activation linker (NTAL) negatively regulates TREM-1/DAP12-induced inflammatory cytokine production in myeloid cells. J Immunol (2007) 1.05
Apoptosis and autophagy: Regulation of apoptosis by DNA damage signalling - roles of p53, p73 and HIPK2. FEBS J (2009) 1.04
Characterization of the heparin/heparan sulfate binding site of the natural cytotoxicity receptor NKp46. Biochemistry (2005) 1.03
Killing of avian and Swine influenza virus by natural killer cells. J Virol (2010) 1.03
Recognition and killing of human and murine pancreatic beta cells by the NK receptor NKp46. J Immunol (2011) 1.01
The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood (2003) 1.00
Memory of infections: an emerging role for natural killer cells. PLoS Pathog (2013) 1.00
Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells. Cancer Res (2005) 0.99
Flamingo cadherin: a putative host receptor for Streptococcus pneumoniae. J Infect Dis (2007) 0.98
Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK2. PLoS One (2011) 0.97
Regulation of triggering receptor expressed on myeloid cells 1 expression on mouse inflammatory monocytes. Immunology (2009) 0.97
Sialylation of 3-methylcholanthrene-induced fibrosarcoma determines antitumor immune responses during immunoediting. J Immunol (2010) 0.96
Identification of Salmonella typhimurium genes responsible for interference with peptide presentation on MHC class I molecules: Deltayej Salmonella mutants induce superior CD8+ T-cell responses. Cell Microbiol (2004) 0.96
Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage. Blood (2013) 0.96
Cutting edge: the AP-1 subunit JunB determines NK cell-mediated target cell killing by regulation of the NKG2D-ligand RAE-1epsilon. J Immunol (2006) 0.95
Expression of ligands to NKp46 in benign and malignant melanocytes. J Invest Dermatol (2007) 0.93
Identification of CLEC12B, an inhibitory receptor on myeloid cells. J Biol Chem (2007) 0.93
Dengue virus replicon expressing the nonstructural proteins suffices to enhance membrane expression of HLA class I and inhibit lysis by human NK cells. J Virol (2008) 0.93
Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. Int J Oncol (2011) 0.92
The natural cytotoxicity receptor 1 contribution to early clearance of Streptococcus pneumoniae and to natural killer-macrophage cross talk. PLoS One (2011) 0.92
Human NK cell recognition of target cells in the prism of natural cytotoxicity receptors and their ligands. J Immunotoxicol (2012) 0.92
Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays. PLoS One (2011) 0.91
Regulatory T cells control macrophage accumulation and activation in lymphoma. Int J Cancer (2010) 0.91
NKp46 O-glycan sequences that are involved in the interaction with hemagglutinin type 1 of influenza virus. J Virol (2010) 0.91
Interaction of human papillomavirus type 16 L2 with cellular proteins: identification of novel nuclear body-associated proteins. Virology (2002) 0.90
Sp100 is important for the stimulatory effect of homeodomain-interacting protein kinase-2 on p53-dependent gene expression. Oncogene (2003) 0.89
Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Int J Oncol (2008) 0.89
Btk is a positive regulator in the TREM-1/DAP12 signaling pathway. Blood (2011) 0.88
Autophosphorylation and Pin1 binding coordinate DNA damage-induced HIPK2 activation and cell death. Proc Natl Acad Sci U S A (2013) 0.88
The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma. Clin Cancer Res (2006) 0.88
Herpes simplex virus immediate-early protein ICP0 is targeted by SIAH-1 for proteasomal degradation. J Virol (2011) 0.88
Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron (2012) 0.87
FLASH meets nuclear bodies: CD95 receptor signals via a nuclear pathway. Cell Cycle (2007) 0.87
NADH oxidase functions as an adhesin in Streptococcus pneumoniae and elicits a protective immune response in mice. PLoS One (2013) 0.87
HIPK2 and cancer cell resistance to therapy. Future Oncol (2008) 0.86
T7 phage display of Ep15 peptide for the detection of WNV IgG. J Virol Methods (2007) 0.86
Regulation of p53 functions: let's meet at the nuclear bodies. Curr Opin Cell Biol (2003) 0.86
PML-associated repressor of transcription (PAROT), a novel KRAB-zinc finger repressor, is regulated through association with PML nuclear bodies. Exp Cell Res (2006) 0.85
Zyxin is a critical regulator of the apoptotic HIPK2-p53 signaling axis. Cancer Res (2011) 0.85
Targeting anti-tumor DNA vaccines to dendritic cells via a short CD11c promoter sequence. Vaccine (2009) 0.84
NF-κ B-dependent upregulation of ICAM-1 by HPV16-E6/E7 facilitates NK cell/target cell interaction. Int J Cancer (2011) 0.83
Streptococcus pneumoniae surface-exposed glutamyl tRNA synthetase, a putative adhesin, is able to induce a partially protective immune response in mice. J Infect Dis (2007) 0.82
Self HSP60 peptide serves as an immunogenic carrier for a CTL epitope against persistence of murine cytomegalovirus in the salivary gland. Vaccine (2005) 0.82
CTLA-4 is expressed by activated mouse NK cells and inhibits NK Cell IFN-γ production in response to mature dendritic cells. J Immunol (2014) 0.82
A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes. Int J Cancer (2006) 0.82
Non-replicating mucosal and systemic vaccines: quantitative and qualitative differences in the Ag-specific CD8(+) T cell population in different tissues. Vaccine (2004) 0.81